Pînzariu Alin Constantin, Moscalu Roxana, Soroceanu Radu Petru, Maranduca Minela Aida, Drochioi Ilie Cristian, Vlasceanu Vlad Ionut, Timofeiov Sergiu, Timofte Daniel Vasile, Huzum Bogdan, Moscalu Mihaela, Serban Dragomir Nicolae, Serban Ionela Lacramioara
Department of Morpho-Functional Sciences II, Discipline of Physiology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Division of Cell Matrix Biology & Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.
Int J Mol Sci. 2025 Mar 27;26(7):3084. doi: 10.3390/ijms26073084.
Mesenchymal stem cells (MSCs) have emerged as a relevant strategy in regenerative medicine due to their multipotent differentiation capacity, immunomodulatory properties, and therapeutic applications in various medical fields. This review explores the therapeutic use of MSCs, focusing on their role in treating autoimmune disorders and neoplastic diseases and in tissue regeneration. We discuss the mechanisms underlying MSC-mediated tissue repair, including their paracrine activity, migration to injury sites, and interaction with the immune system. Advances in cellular therapies such as genome engineering and MSC-derived exosome treatments further enhance their applicability. Key methodologies analyzed include genomic studies, next-generation sequencing (NGS), and bioinformatics approaches to optimize MSC-based interventions. Additionally, we reviewed preclinical and clinical evidence demonstrating the therapeutic potential of MSCs in conditions such as graft-versus-host disease, osteoarthritis, liver cirrhosis, and neurodegenerative disorders. While promising, challenges remain regarding standardization, long-term safety, and potential tumorigenic risks associated with MSC therapy. Future research should focus on refining MSC-based treatments to enhance efficacy and minimize risks. This review underscores the need for large-scale clinical trials to validate MSC-based interventions and fully harness their therapeutic potential.
间充质干细胞(MSCs)因其多能分化能力、免疫调节特性以及在各个医学领域的治疗应用,已成为再生医学中的一种重要策略。本综述探讨了MSCs的治疗用途,重点关注其在治疗自身免疫性疾病、肿瘤性疾病和组织再生中的作用。我们讨论了MSCs介导组织修复的潜在机制,包括其旁分泌活性、向损伤部位的迁移以及与免疫系统的相互作用。细胞疗法如基因组工程和MSCs衍生外泌体治疗的进展进一步提高了它们的适用性。分析的关键方法包括基因组研究、下一代测序(NGS)以及优化基于MSCs的干预措施的生物信息学方法。此外,我们回顾了临床前和临床证据,这些证据证明了MSCs在移植物抗宿主病、骨关节炎、肝硬化和神经退行性疾病等病症中的治疗潜力。尽管前景广阔,但在标准化、长期安全性以及与MSCs治疗相关的潜在致瘤风险方面仍然存在挑战。未来的研究应专注于改进基于MSCs的治疗方法,以提高疗效并将风险降至最低。本综述强调需要进行大规模临床试验,以验证基于MSCs的干预措施并充分发挥其治疗潜力。
Int J Mol Sci. 2025-3-27
Vet Res Commun. 2024-12
Front Immunol. 2021-4-6
Int J Mol Sci. 2024-12-25
Int J Hematol. 2011-12-20
Stem Cell Res Ther. 2023-10-20
BMC Musculoskelet Disord. 2023-6-30
Front Cell Dev Biol. 2023-5-24
Rheumatol Immunol Res. 2022-7-6